Nectar Lifescience Analysis

dividend

Pros

Cons

• Nectar Lifesciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
• No need to calculate the sustainability of Nectar Lifesciences's dividends as it is not paying a notable one for India.
• Nectar Lifesciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
• Nectar Lifesciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
• Nectar Lifesciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

Pros

• Nectar Lifesciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Nectar Lifesciences is profitable, therefore cash runway is not a concern.
• Nectar Lifesciences is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (33.8%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 2.2x debt.
• Nectar Lifesciences's cash and other short term assets cover its long term commitments.
• The level of debt compared to net worth has been reduced over the past 5 years (95.6% vs 69.6% today).

Cons

• Interest payments on debt are not well covered by earnings (EBIT is 2.7x annual interest expense, ideally 3x coverage).
• Nectar Lifesciences's level of debt (69.6%) compared to net worth is high (greater than 40%).
• High level of physical assets or inventory.

management

Pros

• The tenure for the Nectar Lifesciences board of directors is about average.
• Sanjiv's compensation has been consistent with company performance over the past year, both up more than 20%.

Cons

• Sanjiv's remuneration is higher than average for companies of similar size in India.

misc

Pros

Cons

• Nectar Lifesciences is not covered by any analysts.
• Nectar Lifesciences has significant price volatility in the past 3 months.

past

Pros

• Nectar Lifesciences has improved its use of capital last year versus 3 years ago (Return on Capital Employed).

Cons

• Nectar Lifesciences's 1-year earnings growth is negative, it can't be compared to the 5-year average.
• Nectar Lifesciences's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
• Nectar Lifesciences used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• Nectar Lifesciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
• Nectar Lifesciences's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.

value

Pros

• Nectar Lifesciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
• Nectar Lifesciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
• Nectar Lifesciences is good value based on assets compared to the IN Pharmaceuticals industry average.
• Nectar Lifesciences is good value based on earnings compared to the IN Pharmaceuticals industry average.
• Nectar Lifesciences is good value based on earnings compared to the India market.
• 532649 outperformed the Market in India which returned -14.5% over the past year.
• BSE:532649 is up 38.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• BSE:532649 is up 38.9% outperforming the market in India which returned 8% over the past month.

Cons

• 532649 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.